Pivotal LUNAR Study of TTFields + SoC in NSCLC Met Primary Overall Survival Endpoint January 11, 2023
Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Announced January 11, 2023
Initial update on Ph 2 PRESERVE 3 trial of 1L platinum-based chemo and maintenance avelumab +/- trilaciclib in patients with 1L locally advanced or metastatic urothelial carcinoma announced January 11, 2023
Interim Data from Ph 1b/2 Study of Abequolixron (RGX-104) in R/R Lung Cancer Announced January 11, 2023
Positive Top-Line Results from IMerge Ph 3 Trial of Imetelstat in Lower Risk MDS Announced January 11, 2023
Results from INTRIGUE Ph 3 Clinical Study Demonstrate Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Only January 11, 2023
mOS of 21 Months in Advanced, Refractory Cancer Patients observed in Ph 2 trial of PDS0101-based triple combination therapy in advanced HPV-positive cancers January 4, 2023
Complete Response Of The First Patient Treated In B-Cell Non-Hodgkin Lymphoma (B-NHL) Ph 1 Clinical Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 4, 2023
Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel + PD-1i and Carboplatin in Neoadjuvant Breast Cancer reported January 4, 2023
FAILED TRIAL: PEARL Ph 3 trial for Imfinzi (durvalumab) monotherapy did not achieve statistical significance of improving OS vs chemo as a monotherapy treatment in PD-L1+ve mNSCLC patients January 4, 2023
mRNA-4157/V940 + KEYTRUDA® (pembrolizumab) Met Primary Efficacy Endpoint in Ph 2b KEYNOTE-942 Trial December 19, 2022
Zolbetuximab Meets Primary Endpoint in Ph 3 GLOW Trial as 1L Treatment in Claudin 18.2 +ve HER2-neg Locally Advanced Unresectable or Metastatic GEJ Cancers December 19, 2022
Initial Data from the Ongoing Ph 2B VITALIZE Trial in Patients with r/r DLBCL announced December 19, 2022
80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML December 19, 2022
Double-Digit ORR announced in Each Cohort from the Ongoing ENVASARC Ph 2 Pivotal Trial December 19, 2022
Pluvicto™ shows statistically significant & clinically meaningful rPFS benefit in patients with PSMA+ve metastatic CRPC December 12, 2022
PERLA Ph 2 trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in 1L mNSCLC December 12, 2022
New Data from the OPTIMA II Study Shows mDOR of 24.4 Months for UGN-102 in patients with Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer December 12, 2022
Preliminary Results from Trial of Berubicin for the Treatment of Recurrent GBM announced December 12, 2022
FAILED TRIAL: Ph 3 CONTACT-01 trial of cabozantinib + atezolizumab in IO- and chemo-treated mNSCLC patients did not meet its primary endpoint of OS December 12, 2022
Jemperli (Dostarlimab-Gxly) RUBY Ph 3 Trial Met Its Primary Endpoint In A Planned Interim Analysis In Patients With Primary Advanced Or Recurrent Endometrial Cancer December 5, 2022
New Data from the OLYMPUS Trial Shows mDOR of 28.9 Months for JELMYTO for Adults with Low-Grade Upper Tract Urothelial Cancer December 5, 2022
